Fluorescence imaging to improve surgery for liver cancer
Official title: An Evaluation Study of GPC3 Targeted Fluorescence Imaging to Guide the Surgery of Hepatocellular Carcinoma
Run by Chinese Academy of Sciences · NCT05047510 · Data updated 2026-11-12
This study is testing a new imaging technique during liver cancer surgery to see if it helps doctors find tumors more accurately and safely.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Chinese Academy of Sciences Government |
| Locations | 2 sites (Zhuhai, Guangdong and 1 other locations) |
| Status | Recruiting |
| Started | September 10, 2021 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | August 30, 2023 |
| Trial ID | NCT05047510 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 diagnosed with hepatocellular carcinoma who are scheduled for hepatectomy and have liver function classified as Child-Pugh A or B.
✕Probably not a fit
Patients with other malignant tumors, severe organ dysfunction, or those unable to tolerate surgery may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the use of intraoperative fluorescence imaging that targets GPC3 to enhance the surgical accuracy in patients with hepatocellular carcinoma. The approach involves using a novel near-infrared fluorescence molecular imaging technique combined with a GPC-3 targeted fluorophore to increase the detection rate of liver tumors during surgery. The study aims to validate the safety and effectiveness of this imaging method for clinical application in hepatectomy procedures.
Why it matters
Potential benefit: If successful, this could lead to more accurate surgical removal of liver tumors, potentially improving patient outcomes.
How similar studies have gone: Other studies have shown promise in using fluorescence imaging for tumor detection, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who have been diagnosed with hepatocellular carcinoma. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. GPC-3 was validated highly expressed preoperatively. 5. Aged 18 to 75, and the expected lifetime is longer than 6 months. 6. Approved to sign the informed consent. Exclusion Criteria: 1. Allergic to IRDye800. 2. Enrolled in other trials in the past 3 months. 3. Another malignant tumor was found. 4. Undesirable function of heart, lung, kidney, or any other organs. 5. Unable to tolerate a hepatectomy. 6. The researchers considered inappropriate to be included.
Where it's running
-
Zhuhai People's Hospital
Zhuhai, Guangdong, China Recruiting -
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China Recruiting
Study contacts
- Study coordinator: Zeyu Zhang, Ph.D.
- Email: zhangzeyu@fingerpass.net.cn
- Phone: 86-18201082715
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
InstaSure Non-Invasive Finger-Press Test for HCC
This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.
-
BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer
This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.
-
Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer
This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Hepatocellular Carcinoma Patient Registry (CHARM Hepatocellular Carcinoma MEA)
This observational study collects medical records of adults with hepatocellular carcinoma to understand how the disease presents and progresses across regions in the Middle East and North Africa.
-
GLP-1 RA plus standard treatment in first-line metastatic GI cancers
This early-phase trial tests whether adding a GLP-1 receptor agonist to standard first-line chemotherapy is safe and feasible for people with metastatic pancreatic, colorectal, or liver cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.